Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

2.

A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.

Guo H, Liu C, Li J, Zhang M, Hu M, Xu P, Liu L, Liu X.

J Pharm Sci. 2013 Aug;102(8):2819-36. doi: 10.1002/jps.23613. Epub 2013 Jun 11.

PMID:
23760985
3.

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.

Asaumi R, Toshimoto K, Tobe Y, Hashizume K, Nunoya KI, Imawaka H, Lee W, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):186-196. doi: 10.1002/psp4.12275. Epub 2018 Feb 5.

4.

A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.

Wang J, Xia S, Xue W, Wang D, Sai Y, Liu L, Liu X.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):290-302. doi: 10.1016/j.ejps.2013.07.012. Epub 2013 Jul 31.

PMID:
23916407
5.

Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.

Baneyx G, Parrott N, Meille C, Iliadis A, Lavé T.

Eur J Pharm Sci. 2014 Jun 2;56:1-15. doi: 10.1016/j.ejps.2014.02.002. Epub 2014 Feb 12.

PMID:
24530864
7.

Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T.

AAPS J. 2017 Jan;19(1):298-312. doi: 10.1208/s12248-016-0009-9. Epub 2016 Nov 7.

PMID:
27822600
8.

Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.

J Pharm Sci. 2013 Sep;102(9):3161-73. doi: 10.1002/jps.23607. Epub 2013 May 19.

PMID:
23686764
9.

Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.

Narayanan R, Hoffmann M, Kumar G, Surapaneni S.

Drug Metab Lett. 2016;10(3):172-179.

PMID:
27604990
10.

Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.

Kimoto E, Vourvahis M, Scialis RJ, Eng H, Rodrigues AD, Varma MVS.

Drug Metab Dispos. 2019 May;47(5):493-503. doi: 10.1124/dmd.118.085241. Epub 2019 Mar 12.

PMID:
30862625
11.

Physiologically Based Pharmacokinetic Modeling of Palbociclib.

Yu Y, Loi CM, Hoffman J, Wang D.

J Clin Pharmacol. 2017 Feb;57(2):173-184. doi: 10.1002/jcph.792. Epub 2016 Aug 22.

PMID:
27402157
12.

Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.

Budha NR, Ji T, Musib L, Eppler S, Dresser M, Chen Y, Jin JY.

Clin Pharmacokinet. 2016 Nov;55(11):1435-1445.

PMID:
27225997
13.

Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.

Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, Bouzom F.

Clin Pharmacokinet. 2010 Apr;49(4):239-58. doi: 10.2165/11318130-000000000-00000.

PMID:
20214408
14.

Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.

Marzolini C, Rajoli R, Battegay M, Elzi L, Back D, Siccardi M.

Clin Pharmacokinet. 2017 Apr;56(4):409-420. doi: 10.1007/s40262-016-0447-7.

PMID:
27599706
15.

Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.

Greupink R, Schreurs M, Benne MS, Huisman MT, Russel FG.

Eur J Pharm Sci. 2013 Aug 16;49(5):819-28. doi: 10.1016/j.ejps.2013.06.009. Epub 2013 Jun 24.

PMID:
23806476
16.

Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.

Marsousi N, Desmeules JA, Rudaz S, Daali Y.

Biopharm Drug Dispos. 2018 Jan;39(1):3-17. doi: 10.1002/bdd.2107. Epub 2017 Nov 20.

PMID:
28960401
17.
18.

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.

Lin J, Goosen TC, Tse S, Yamagami H, Malhotra B.

J Clin Pharmacol. 2019 May 14. doi: 10.1002/jcph.1438. [Epub ahead of print]

PMID:
31090092
19.
20.

PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.

Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T.

CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):647-659. doi: 10.1002/psp4.12343. Epub 2018 Sep 7.

Supplemental Content

Support Center